Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sumitomo Pharma CoDNPUF 65 EV-to-EBITDA is 5.96 as of Jul. 30, 2026, which is 21% below its 10-year median of 7.56. GuruFocus rates DNPUF with a GF Score™ of 65/100 and a GF Value™ of $5.49 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 745 Drug Manufacturers companies, Sumitomo Pharma Co ranks better than 78.52% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sumitomo Pharma Co's enterprise value is $4,488 Mil.
Sumitomo Pharma Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $753 Mil. Therefore, Sumitomo Pharma Co's EV-to-EBITDA for today is 5.96.
The historical rank and industry rank for Sumitomo Pharma Co's EV-to-EBITDA or its related term are showing as below:
DNPUF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.8 Med: 7.56 Max: 19.93
Current: 6.73
During the past 13 years, the highest EV-to-EBITDA of Sumitomo Pharma Co was 19.93. The lowest was -9.80. And the median was 7.56.
DNPUF's EV-to-EBITDA is ranked better than 78.52% of 745
companies
in the Drug Manufacturers industry
Industry Median: 12.91
vs DNPUF: 6.73
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Sumitomo Pharma Co (OTCPK:DNPUF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sumitomo Pharma Co's PE Ratio (TTM) for today is calculated as:
Sumitomo Pharma Co's share price for today is $8.405.
Sumitomo Pharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.816.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Sumitomo Pharma Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sumitomo Pharma Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sumitomo Pharma Co's EV-to-EBITDA falls into.
Sumitomo Pharma Co's current Enterprise Value is $4,488 Mil.
Sumitomo Pharma Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $753 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sumitomo Pharma Co (DNPUF) has a EV-to-EBITDA of 5.96 as of Jul. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sumitomo Pharma Co. This is 21% below median its historical median of 7.56. According to the industry distribution chart, Sumitomo Pharma Co ranks #160 out of 745 companies in the Drug Manufacturers industry, placing it in the top 21.5%.
Is Sumitomo Pharma Co's EV-to-EBITDA too high?
Sumitomo Pharma Co's current EV-to-EBITDA of 5.96 is 21% below median its 10-year median of 7.56. The Drug Manufacturers industry median EV-to-EBITDA is 12.91. Sumitomo Pharma Co's value of 5.96 is 53.8% below this industry median. Based on the distribution chart, Sumitomo Pharma Co ranks #160 out of 745 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sumitomo Pharma Co has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sumitomo Pharma Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sumitomo Pharma Co ranks #160 out of 745 companies for EV-to-EBITDA. This places Sumitomo Pharma Co in the top 22% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 12.91. Sumitomo Pharma Co's value of 5.96 is 53.8% below this benchmark. While the company's 10-year median is 7.56 vs. the industry median of 12.91, Sumitomo Pharma Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.91, based on 745 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sumitomo Pharma Co's current EV-to-EBITDA of 5.96 is 53.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sumitomo Pharma Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sumitomo Pharma Co's current EV-to-EBITDA is 5.96, which is 21% below median its own 10-year median of 7.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sumitomo Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Sumitomo Pharma Co (DNPUF) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.49, compared to a current price of $8.41 — trading 53.1% above its estimated fair value. The current EV-to-EBITDA is 5.96, which is 21% below median its 10-year median of 7.56 and 53.8% below the Drug Manufacturers industry median of 12.91. Sumitomo Pharma Co's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sumitomo Pharma Co (DNPUF), the current EV-to-EBITDA is 5.96 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sumitomo Pharma Co (DNPUF) Overvalued in 2026?
Based on GuruFocus' analysis, Sumitomo Pharma Co stock appears to be overvalued.
The current stock price of $8.41 is trading 53.1% above its estimated GF Value™ of $5.49.
GuruFocus considers Sumitomo Pharma Co to be Significantly Overvalued.
Key valuation signals for DNPUF:
EV-to-EBITDA: 5.96 (21% below median its 10-year median of 7.56)
GF Value™: $5.49 vs. price of $8.41 (53.1% above fair value)
Industry Position: 53.8% below the Drug Manufacturers median (#160 of 745)
No single metric tells the full story. See the DNPUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
65GF Score
Get the complete analysis for DNPUF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DNPUF has been successfully added to your 
